The results from the first randomized, placebo-controlled study for Gilead Sciences Inc.’s remdesivir in China have seemingly disappointed, but some say the repurposed antiviral may still go on to get a regulatory approval for COVID-19.
Originally designed to enroll 237 patients, the study was terminated early due to a lack of participants in Wuhan, the former epicenter of the global outbreak where patients have been...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?